Patent: 9,821,043
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,821,043
Title: | Anti-HER2 vaccine based upon AAV derived multimeric structures |
Abstract: | The present invention relates to parvovirus mutated structural proteins comprising insertions of mimotopes of a HER2, compositions, multimeric structures, medicaments and vaccines comprising the same, nucleic acids, expression cassettes, constructs, vectors and cells comprising the nucleic acids, methods of preparing the structural proteins and methods of inducing a B-cell response or of treating a HER2-related disease. |
Inventor(s): | Michaelis; Uwe (Weilheim, DE), Jensen-Jarolim; Erika (Vienna, AT), Rehfuess; Christoph (Munchen, DE), Weghofer; Margit (Vienna, AT) |
Assignee: | Medigene AG (Planegg-Martinsried, DE) |
Application Number: | 14/344,783 |
Patent Claims: | see list of patent claims |
Details for Patent 9,821,043
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2031-09-15 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2031-09-15 |
Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | 06/08/2012 | ⤷ Try a Trial | 2031-09-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |